Back to top
more

Integra LifeSciences (IART)

(Real Time Quote from BATS)

$28.75 USD

28.75
55,486

-0.49 (-1.68%)

Updated Apr 30, 2024 10:31 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 46% (136 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut

by Zacks Equity Research

In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.

Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 24.56% and 1.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Device Stocks' Q2 Earnings on Jul 27: BSX, LH & IART

by Urmimala Biswas

Medical Device companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, LH and IART fare this time.

OrthoPediatrics (KIDS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

OrthoPediatrics (KIDS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra's (IART) Codman EVD Catheter Study Data Favorable

by Zacks Equity Research

Integra's (IART) Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus.

Integra (IART) Completes Enrollment in the DuraSorb IDE Study

by Zacks Equity Research

Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.

New Strong Sell Stocks for June 29th

by Zacks Equity Research

NGVT, IART and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2023.

Here's Why You Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.

Integra (IART) Builds Advanced R&D Facility in New Jersey

by Zacks Equity Research

Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.

Integra's (IART) Q1 Earnings Match Estimates, Margins Contract

by Zacks Equity Research

In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.

Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Integra LifeSciences (IART) Q1 Earnings Meet Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y

by Zacks Equity Research

Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.

Integra LifeSciences (IART) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Artivion (AORT) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DexCom (DXCM) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 30.77% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

by Urmimala Biswas

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

Accuray (ARAY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 7.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Integra (IART) Could Beat Earnings Estimates Again

by Zacks Equity Research

Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.